Metopirone 250 mg capsules    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
75クッシング病4

75. クッシング病 [臨床試験数:191,薬物数:172(DrugBank:48),標的遺伝子数:61,標的パスウェイ数:121
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 191 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-000162-22-DE
(EUCTR)
04/05/201530/10/2014Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone
INN or Proposed INN: METYRAPONE
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 4Hungary;Poland;Romania;Germany;Italy;Spain;Belgium;Turkey
2EUCTR2014-000162-22-IT
(EUCTR)
19/03/201525/11/2014Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules/Cormeto
Product Name: metyrapone
INN or Proposed INN: METYRAPONE
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 4United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden
3EUCTR2014-000162-22-BE
(EUCTR)
11/03/201504/12/2014Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 4United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden
4EUCTR2014-000162-22-ES
(EUCTR)
23/02/201516/01/2015Study to assess the effects of metyrapone in patients with Cushing?s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing?s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing?s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone
INN or Proposed INN: METYRAPONE
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 3United States;Hungary;Poland;Belgium;Spain;Germany;Italy;Switzerland;Sweden